Ratish Krishnan, David Loong, and Nargisse El Hajjami of MilliporeSigma discuss the challenges to gene therapy development and manufacturing created by the pandemic and lessons learned from the rapid vaccine development efforts that can be applied to transform the gene therapy field going forward.
.svg)
